Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally advanced cervical cancer was not cost-effective in an economic evaluation ...

Bradley Monk shares key insights and breakthroughs in gynaecologic oncology from ESGO 2025, shaping cancer care's future.

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

This is the same drug which cervical cancer campaigner Vicky ... “Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, evaluated ...

Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...